Brentuximab Vedotin Plus Doxorubicin, Vinblastine, Dacarbazine (A plus AVD) As Frontline Therapy Demonstrates Superior Modified Progression-Free Survival Versus ABVD in Patients with Previously Untreated Stage III or IV Hodgkin Lymphoma (HL): The Phase 3 Echelon-1 Study

被引：0
|
作者：
Connors, Joseph M.
Jurczak, Wojciech
Straus, David J.
Ansell, Stephen M.
Kim, Won Seog
Gallamini, Andrea
Younes, Anas
Alekseev, Sergei
Illes, Arpad
Picardi, Marco
Lech-Maranda, Ewa
Oki, Yasuhiro
Feldman, Tatyana A.
Smolewski, Piotr
Savage, Kerry J.
Bartlett, Nancy L.
Walewski, Jan
Chen, Robert W.
Ramchandren, Rod
Zinzani, Pier Luigi
Cunningham, David
Heo, Dae Seog
Rosta, Andras
Josephson, Neil
Ruffner, Katherine L.
Sachs, Jessica
Liu, Rachael
Jolin, Hina
Huebner, Dirk
Radford, John A.
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
6
引用
收藏
页数：4
相关论文
共 28 条
  • [21] Phase 1 Results from a Phase 1/2 Study to Assess the Safety, Tolerability and Recommended Phase 2 Dose (RP2D) of Brentuximab Vedotin Plus Doxorubicin, Vinblastine and Dacarbazine (A plus AVD) in Pediatric Patients (Pts) with Advanced Stage Newly Diagnosed Classical Hodgkin Lymphoma (cHL)
    Franklin, Anna
    Zecca, Marco
    Fagioli, Franca
    Luisi, Flavio Augusto
    Song, Gregory
    Suri, Ajit
    Leonard, E. Jane
    Locatelli, Franco
    BLOOD, 2018, 132
  • [22] An Oncology Simulation Model to Estimate 10-Year Overall Survival, Progression-Free Survival, and Stem Cell Transplantation for Frontline, Stage III or IV Classic Hodgkin Lymphoma Based on the Overall Survival Update of the ECHELON-1 Trial: A United States Perspective
    Phillips, Tycel
    Migliaccio-Walle, Kristen
    Yu, Kristina
    Bloudek, Brian
    Liu, Nicholas
    Burke, John
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S349 - S350
  • [23] An Oncology Simulation Model to Estimate 10-Year Progression-Free Survival and Stem Cell Transplantation for Frontline, Stage III or IV Classical Hodgkin Lymphoma Based on the 5-Year Update of the ECHELON-1 Trial: A United States Perspective
    Phillips, Tycel
    Migliaccio-Walle, Kristen
    Yu, Kristina S.
    Bloudek, Brian
    Liu, Nicholas
    Fanale, Michelle A.
    Burke, John M.
    BLOOD, 2021, 138
  • [24] ECHELON-2 (NCT01777152), a randomized, double-blind, phase 3 study of brentuximab vedotin plus cyclophosphamide doxorubicin and prednisone versus cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with CD30-positive peripheral T-cell lymphoma: 5-year results
    Illidge, Timothy
    Horwitz, Steven M.
    O'Connor, Owen A.
    Pro, Barbara
    Iyer, Swami P.
    Advani, Ranjana
    Bartlett, Nancy L.
    Christensen, Jacob Haaber
    Morschhauser, Franck
    Domingo-Domenech, Eva
    Rossi, Giuseppe
    Kim, Won Seog
    Feldman, Tatyana A.
    Menne, Tobias
    Belada, David
    Illes, Arpad
    Tobinai, Kensei
    Tsukasaki, Kunihiro
    Yeh, Su-Peng
    Huettmann, Andreas
    Savage, Kerry J.
    Yuen, Sam
    Zinzani, Pier Luigi
    Miao, Harry
    Bunn, Veronica
    Fenton, Keenan
    Fanale, Michelle A.
    Puhlmann, Markus
    Truemper, Lorenz
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 38 - 40
  • [25] Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma: Part 3 (Concurrent Dosing) Results and Updated Progression-Free Survival Results from Parts 1 and 2 (Staggered Dosing)
    Advani, Ranjana H.
    Moskowitz, Alison J.
    Bartlett, Nancy L.
    Vose, Julie M.
    Ramchandren, Radhakrishnan
    Feldman, Tatyana A.
    LaCasce, Ann S.
    Christian, Beth A.
    Ansell, Stephen M.
    Moskowitz, Craig H.
    Fenton, Keenan
    Ogden, Carol Anne
    Taft, David
    Zak, Daniel E.
    Sacchi, Mariana
    Galderisi, Faith
    Herrera, Alex F.
    BLOOD, 2018, 132
  • [26] Polatuzumab Vedotin plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma: Results from the Phase III POLARIX Study
    Tilly, Herve
    Morschhauser, Franck
    Sehn, Laurie H.
    Friedberg, Jonathan W.
    Trneny, Marek
    Sharman, Jeff P.
    Herbaux, Charles
    Burke, John M.
    Matasar, Matthew
    Rai, Shinya
    Izutsu, Koji
    Mehta-Shah, Neha
    Oberic, Lucie
    Chauchet, Adrien
    Jurczak, Wojciech
    Song, Yuqin
    Greil, Richard
    Mykhalska, Larysa
    Miguel, Juan
    Burgues, Bergua
    Cheung, Matthew C.
    Pinto, Antonio
    Shin, Ho-Jin
    Hapgood, Greg
    Munhoz, Eduardo
    Abrisqueta, Pau
    Gau, Jyh-Pyng
    Hirata, Jamie
    Jiang, Yanwen
    Yan, Mark
    Lee, Calvin
    Flowers, Christopher
    Salles, Gilles
    Collins, Graham
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 14 - 16
  • [27] Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results From the Phase III POLARIX Study
    Flowers, Christopher
    Tilly, Herve
    Morschhauser, Franck
    Sehn, Laurie H.
    Friedberg, Jonathan W.
    Trneny, Marek
    Sharman, Jeff P.
    Herbaux, Charles
    Burke, John M.
    Matasar, Matthew
    Rai, Shinya
    Izutsu, Koji
    Mehta-Shah, Neha
    Oberic, Lucie
    Chauchet, Adrien
    Jurczak, Wojciech
    Song, Yuqin
    Greil, Richard
    Mykhalska, Larysa
    Bergua-Burgues, Juan Miguel
    Cheung, Matthew C.
    Pinto, Antonio
    Shin, Ho-Jin
    Hapgood, Greg
    Munhoz, Eduardo
    Abrisqueta, Pau
    Gau, Jyh-Pyng
    Hirata, Jamie
    Jiang, Yanwen
    Yan, Mark
    Lee, Calvin
    Salles, Gilles
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S358 - S359
  • [28] Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-r-chp) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (r-chop) therapy in patients with previously untreated diffuse large b-cell lymphoma (dlbcl): results from the phase iii polarix study
    Dietrich, Sascha
    Tilly, Herve
    Morschhauser, Franck
    Sehn, Laurie H.
    Friedberg, Jonathan W.
    Trneny, Marek
    Sharman, Jeff
    Herbaux, Charles
    Burke, John M.
    Matasar, Matthew
    Rai, Shinya
    Izutsu, Koji
    Mehta-Shah, Neha
    Oberic, Lucie
    Chauchet, Adrien
    Jurczak, Wojciech
    Song, Yu Qin
    Greil, Richard
    Mykhalska, Larysa
    Bergua Burgues, Juan Miguel
    Cheung, Matthew C.
    Pinto, Antonio
    Shin, Ho-Jin
    Hapgood, Greg
    Munhoz, Eduardo
    Salles, Gilles
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 165 - 165
123